US2005201973A1PendingUtilityA1

Therapeutic supramolecules

57
Priority: Oct 31, 1994Filed: Nov 9, 2004Published: Sep 15, 2005
Est. expiryOct 31, 2014(expired)· nominal 20-yr term from priority
Inventors:Jorma VirtanenSinikka Virtanen
A61P 31/12Y10S530/812A61K 47/6911A61K 9/1271Y10S977/907G01N 33/535A61K 47/56C07K 19/00A61K 38/00A61P 43/00A61K 47/6807C12N 15/88A61P 9/10C12Q 1/68A61K 47/68C07K 2319/00A61K 47/6839C07K 16/1145
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A therapeutic supramolecule including a first component having a binding effector molecule such as a protein, a polypeptide, a lipid, or a sugar; and a second component including a therapeutic effector molecule such as a protein, a polypeptide, a lipid, or a sugar, where the binding effector molecule and therapeutic effector molecule are linked by a joining molecule, a peptide, or a dendrimer.

Claims

exact text as granted — not AI-modified
1 . A therapeutic supramolecule comprising: 
 a first component comprising at least one binding effector molecule selected from the group consisting of a protein, a polypeptide, a lipid, and a sugar; and    a second component comprising at least one therapeutic effector molecule selected from the group consisting of: a protein, a polypeptide, a lipid, and a sugar, wherein said binding effector molecule and said therapeutic effector molecule are linked by a dendrimer.    
     
     
         2 . A therapeutic supramolecule comprising: 
 a first component comprising a binding effector molecule selected from the group consisting of a protein, a polypeptide, a lipid, and a sugar; and    a second component comprising a therapeutic effector molecule selected from the group consisting of: a protein, a polypeptide, a lipid, and a sugar, wherein said binding effector molecule and said therapeutic effector molecule are linked by a peptide.    
     
     
         3 . A therapeutic supramolecule comprising: 
 a first component comprising a binding effector molecule selected from the group consisting of: a protein, a polypeptide, a lipid, and a sugar; and    a second component comprising a therapeutic effector molecule selected from the group consisting of a protein, a polypeptide, a lipid, and a sugar, wherein said binding effector molecule and said therapeutic effector molecule are functionally linked by a joining molecule.

Join the waitlist — get patent alerts

Track US2005201973A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.